Melatonin Induces Cell Apoptosis in AGS Cells Through the Activation of JNK and P38 MAPK and the Suppression of Nuclear Factor-Kappa B: a Novel Therapeutic Implication for Gastric Cancer

Weimin Li\textsuperscript{a} Mengdi Fan\textsuperscript{b} Yina Chen\textsuperscript{a} Qian Zhao\textsuperscript{a} Caiyun Song\textsuperscript{a} Ye Yan\textsuperscript{a} Yin Jin\textsuperscript{a} Zhiming Huang\textsuperscript{a} Chunjing Lin\textsuperscript{a} Jiansheng Wu\textsuperscript{a}

\textsuperscript{a}Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, \textsuperscript{b}Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Key Words
Melatonin • Apoptosis • Mitogen-activated protein kinases • Nuclear factor-kappa B

Abstract
Background/Aims: Melatonin, synthesized by the pineal gland and released into the blood, appears to have antitumour properties; however, the mechanisms of its anti-cancer effects are largely unknown, especially in stomach cancer. Here, we explore the antitumour activity of melatonin in a gastric cancer cell line (AGS) and analyse its molecular mechanisms. Methods: AGS cells were treated with melatonin, and cell viability was assessed using a CCK-8 assay. Flow cytometry was performed to evaluate apoptosis, and protein expression was examined by Western blotting. Results: Melatonin significantly inhibited cell viability, clone formation, and cell migration and invasion and induced apoptosis in AGS cells. Moreover, MAPK pathways (p38, JNK and ERK) were activated by melatonin treatment, which also significantly increased caspase-3 cleavage and Bax protein expression and decreased Bcl-2 protein expression in a time-dependent manner. Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-κB p65 activation by p38 and JNK. Finally, melatonin was able to strengthen cisplatin-mediated antitumour effects in human gastric carcinoma cells by up-regulating the expression of Bax, down-regulating the expression of Bcl-2 and activating the caspase-dependent apoptotic pathway. Conclusion: Melatonin induced apoptosis in AGS cells by activating the caspase-dependent apoptotic pathway and by inhibiting the nuclear translocation of NF-κB p65, two processes that are regulated by p38 and JNK. Furthermore, melatonin significantly enhanced...
the anti-tumour effects of cisplatin, with low systemic toxicity. These new findings suggest that melatonin may act as a potent anti-tumour agent and may have great potential as an adjuvant therapy in the future.

Introduction

Gastric cancer is one of the most common malignancies and is associated with a high mortality rate worldwide [1]. Asian patients tend to be diagnosed at an early age (66.8 years) and have extremely poor survival rates [2]. In general, conventional surgery and chemotherapy have improved overall survival, though not to a sufficient extent. Thus, identifying an efficient drug therapy for gastrointestinal tract cancer is an important focus of research, and more effective drugs or comprehensive therapies are required [3].

Melatonin (N-acetyl-5-methoxytryptamine), a pineal gland hormone, regulates sleep and circadian rhythm and also affects other important regulatory processes [4]. Indeed, melatonin plays significant roles in a wide variety of biological processes, including immunomodulation, anti-inflammation and oxidative stress responses [5-8]; some research has even shown that melatonin promotes cell survival in normal tissues [9-11] and that the antioxidant potential of melatonin may prevent cell death under both physiological and pathological conditions [12]. Melatonin also demonstrates oncostatic effects in different types of cancer [13-15]. Although the underlying molecular mechanism of the anti-cancer effects of melatonin in gastric cancer is largely unknown, various studies have reported that the anti-tumour capacity of melatonin may be mediated by several mechanisms, including the activation of anti-oxidation, the inhibition of migration and the induction of apoptosis in tumours [16-18]. A recent study reported that melatonin decreased B-cell lymphoma 2 (Bcl-2) and increased Bcl-2-associated X (Bax) protein expression at both the mRNA and protein levels in murine foregASTatic carcinoma cells [16]. The pro-apoptotic effect of melatonin has also been shown in human gastric cancer cells (SGC7901) [19].

The mitogen-activated protein kinase (MAPK) pathway is a key signal transmission network in eukaryotes and plays important roles in cell survival and proliferation [20]. The MAPK family has been divided into three main groups: p38 MAPK, c-jun N-terminal kinase (JNK) and extracellular-regulated kinase 1/2 (ERK1/2) [21]. Recently, an increasing number of studies have demonstrated that p38 MAPK and JNK substrates are linked to cell growth and apoptosis [22], are implicated in cancer development and are affected by melatonin [23]. Tana et al. found that melatonin can suppress the transcription, translation and activity of MLCK through ERK1/2 signal transduction in the oesophageal epithelium of GERD patients [24].

Nuclear factor kappa B (NF-κB) belongs to the Rel family, which consists of p50, p52, c-Rel, RelA (p65) and RelB. As a transcription factor, NF-κB stimulates the expression of many genes related to oxidative stress, cytokine production and anti-apoptosis [25]. It has been reported that melatonin could suppress the NF-κB pathway in rat endothelial cells [26] and murine macrophages [27]. In addition, melatonin disturbs the synthesis of NO and the expression of the inducible isoform of nitric oxide synthase (iNOS) by suppressing the nuclear translocation of NF-κB [26, 27].

However, it is unknown whether melatonin influences apoptosis in human gastric cancer cells (e.g., AGS cells) via the p38, JNK and ERK signalling pathways. Thus, we investigated the effect of melatonin on the viability and apoptosis of AGS cells through MAPK pathways and examined whether melatonin induces apoptosis by decreasing the nuclear translocation of NF-κB via MAPK pathways. Because these pathways are at the junction of several signalling cascades, including those involved in various physiological and pathological processes, MAPK pathways may be associated with NF-κB. Additionally, to assess the potential influence of melatonin on tumour chemotherapy, we also evaluated whether melatonin could enhance the anti-cancer effect of cisplatin in human gastric cancer cells.
Materials and Methods

Cell culture and reagents

Human gastric cancer AGS cells were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China), and human gastric mucosal cells (GES-1) were obtained from the American Type Culture Collection (Manassas, VA, USA). Samples of approximately 5 x 10⁵ cells per flask were cultured in Roswell Park Memorial Institute-1640 medium (RPMI 1640; Sigma, St. Louis, MO, USA) supplemented with 10% heat-inactivated foetal bovine serum (FBS; Sigma, St. Louis, MO, USA), 100 U/ml penicillin and 100 µl/ml streptomycin at 37°C with 5% CO₂ in a humidified incubator. The culture medium was renewed every 2 days. The cells were treated with different concentrations of melatonin at different times. Melatonin was purchased from Sigma (St. Louis, MO, USA), dissolved in dimethylsulfoxide (DMSO; Waltham, MA, USA) to different stock concentrations (0.125, 0.25, 0.5, 1, and 2 M) and diluted with culture medium to 0.25, 0.5, 1, 2, and 4 mM immediately before use. Thus, the cells were exposed to DMSO at 0.2%; DMSO concentrations less than 1% have limited effects on cell behaviour [28].

Antibodies against phospho-p38 ((Thr180/Tyr182) rabbit mAb #9215), p38 ((D13E1) rabbit mAb #8690), phospho-Erk1/2 ((Thr202/Tyr204) rabbit mAb #4370), Erk1/2 ((137F5) rabbit mAb #4695), phospho-JNK ((Thr183/Tyr185) rabbit mAb #4668), JNK (#9252), phospho-NF-κB p65 ((Ser536) rabbit mAb #3033), NF-κB p65 ((D14E12) rabbit mAb #8242), caspase-3 (#9662) and Bcl-2 (#4223) were purchased from Cell Signaling Technology (Beverly, MA, USA). Bax and GAPDH were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). The anti-β-Actin antibody was purchased from Abcam (Cambridge, MA, USA). Cisplatin was obtained from QiLu Pharmaceutical Corporation (Shandong, China).

Colony-forming assays

AGS cells were incubated in six-well plates (5 x 10⁵ cells/well) at 37°C in a humidified atmosphere containing 5% CO₂. On the following day, the cells were treated with 1 and 2 mM melatonin for 8 days. Then, each well was washed twice with phosphate-buffered saline (PBS) and stained with Crystal Violet. During the 8-day incubation, the medium in all wells was changed every 48 h.

Cell viability assay

The Cell Count Kit-8 (CCK-8; Dojindo, Japan) was used to assess the effect of melatonin on cell viability. For the CCK-8 assay, cells were seeded into 96-well culture plates (4 x 10³ cell/well) in 200 µl of complete medium; the plating medium was refreshed after 24 h. Melatonin was dissolved in fresh medium at different doses (0.5 - 4 mM); vehicle control cells were incubated in culture medium supplemented with 0.2% DMSO. Each group consisted of five parallel wells. After incubation for 12, 24, 48 and 72 h, CCK-8 was added to the culture media, and the supernatant of each well was measured at a wavelength of 450 nm using a plate reader (Infinite® 200 PRO NanoQuant; Tecan Austria GmbH Untersbergstr, Austria). Each experiment was performed in triplicate. Cell viability in each group was calculated as the absorbance of the melatonin-treated sample/cell control absorbance x 100.

Wound healing assay

AGS cells were seeded in complete medium in 12-well plates at a density of 3 x 10⁴ cells/well at 37°C with 5% CO₂. When the cells formed a monolayer, a scratch was generated in the middle of the well with a 100-µl pipette tip. Subsequently, the debris was removed, the plates were rinsed with PBS, and the cells were cultured with fresh media with different concentrations of melatonin (0 - 2 mM) and 0.2% DMSO. After incubation for 0, 24 and 48 h, the cells were imaged using a phase-contrast microscope; each experiment was performed in triplicate. The initial migration of the scratch in the field of view was determined by the area divided by the length devoid of cells using Image-Pro Plus software (Media Cybernetics Co., Bethesda, MD). The results are expressed as the difference in migration distance between 0 h and 48 h of treatment.

Invasion assay

A cell migration assay was performed using 24-well Transwell chambers with 8-µm polycarbonate nucleopore filters, which were coated with 10 µg/well Matrigel. Briefly, after treatment with 2 mM melatonin, tumour cells were trypsinized and added to the upper Matrigel-coated chamber at a density of 3 x 10⁴ cells/well in serum-free medium; 10% FBS-containing medium was added to the lower chamber.
After 24 h, the cells that had invaded through the Matrigel and adhered to the bottom of the membrane were fixed with 4% paraformaldehyde for 15 min at room temperature and then stained with Crystal Violet for 20 min. Next, the chambers were washed with PBS, and the upper surface of the membrane was wiped with a cotton swab to remove non-migratory cells. The cells on the lower surface were identified as invasive cells and were visualized using phase-contrast microscopy; the cells were counted using ImageJ software.

**Apoptosis assay using Annexin-V FITC/PI**
FITC-conjugated Annexin-V and propidium iodide (PI) (MultiSciences Biotech, Zhejiang, China) staining was used to detect the extent of early apoptosis and necrosis. Cells (4 × 10⁵) were plated in 6-well plates and treated with 2 mM melatonin for 0 h to 48 h. The cells were harvested by trypsinization, washed with PBS, centrifuged at 1 × 10³ rpm for 5 min and resuspended in 1 × binding buffer. Next, 500 μl of each sample solution was added to 5 μl of FITC-conjugated Annexin-V and 10 μl of PI followed by incubation for 5 min in the dark at room temperature. The samples were subjected to flow cytometry using a fluorescence-activated cell sorter and quantified using FlowJo software. Positioning of the quadrants on Annexin-V FITC/PI dot plots was used to distinguish among living cells (Annexin-V FITC⁻/PI⁻), early apoptotic cells (Annexin-V FITC⁺/PI⁻) and late apoptotic/secondary necrotic cells (Annexin-V FITC⁺/PI⁺) [23].

**Immunofluorescence assay**
To investigate the association between melatonin and NF-κB activation, NF-κB protein localization in AGS cells was investigated by an immunofluorescence assay. Cells (4 × 10⁵) were incubated on coverslips in 6-well plates and treated with 2 mM melatonin for 24 h. The coverslips were washed three times with PBS and fixed with 4% paraformaldehyde for 20 min. The coverslips were washed with PBS to remove the paraformaldehyde, and 1% Triton X-100 was added for 5 min to promote cell membrane permeability. After blocking with 1% BSA, the cells were incubated with an anti-p65 antibody (Cell Signaling Technology, Beverly, MA, USA), and then an appropriate anti-rabbit secondary fluorescent antibody. Finally, the cells were stained with DAPI in the dark at room temperature. Images were captured using a Leica spectral confocal laser scanning microscope.

**Western blot analysis**
Cultured cells were homogenized in ice-cold RIPA buffer containing 50 mM Tris–HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride, EDTA, PMSF and PhosSTOP (Roche, Basel, Switzerland) for 30 min on ice. The cells were scraped off the plate, and the extracts were transferred to a microcentrifuge tube and centrifuged at 1.2 × 10⁴ g for 20 min. The protein concentration was determined by the BCA assay (Beyotime). Equal amounts of total protein (40 μg) were separately subjected to 10-12% SDS-PAGE and then transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA) at 350 mA for 0.5 - 1 h. The membranes were blocked at 25°C for 1 h in blocking buffer (TBS, 0.1% Tween-20, and 5% non-fat dry milk) and then immunoblotted overnight at 4°C with primary antibodies targeted against the following: phospho-p38, p38, phospho-ERK, ERK, phospho-JNK, JNK, phospho-p65, p65, Bcl-2, caspase-3, Bax and GAPDH (1:1000). After washing with TBS (pH 8.0) containing 0.1% Tween-20, the membranes were incubated for 1 h at room temperature with goat anti-rabbit secondary IgG conjugated to horseradish peroxidase (HRP) (1:10,000; Bioworld Technology Inc, Minnesota, USA) and then washed with TBS containing 0.1% Tween-20. Finally, the protein bands were visualized using a Western Bright ECL detection kit (Advansta, Menlo Park, California, USA). The density of specific bands was quantified using Image Lab software (Bio-Rad, Hercules, California, USA) with an imaging densitometer (Bio-Rad ChemiDoc MP, Hercules, California, USA). The blots were also subjected to densitometry using GAPDH or β-actin as an internal control.

**Statistical analysis**
The results were analysed using SPSS software (v. 13) (Chicago, IL, USA). The data, which were expressed as percentages of the control, are reported as the means ± S.E.M. Analysis of variance (ANOVA) was used for data comparisons; when the analysis showed the presence of a significant difference, the data were compared using the Newman–Keuls post-test. Statistical significance was accepted at \( P < 0.05 \).
Results

Effects of melatonin on AGS cell viability, colony formation, invasion, motility and apoptosis

We employed a human gastric cancer cell line (AGS) to assess the anti-cancer effects of melatonin on stomach carcinoma cells. The effect of melatonin on AGS cell viability was investigated using the CCK-8 assay, and cell viability was found to be significantly reduced by 1 mM melatonin after 24 h of treatment (87% viability, Fig. 1A), with a maximum effect observed after 72 h using 4 mM melatonin (5% viability, Fig. 1A). A similar result was obtained when analysing the number of colonies formed, with significant decreases induced by melatonin treatment (1 mM and 2 mM) (Fig. 1B).

To evaluate the influence of melatonin on cell migration, cells were treated with varying concentrations of melatonin for various times. As shown in Fig. 2A, 2 mM melatonin dramatically reduced AGS cell migration (52% of control at 48 h). To further examine the inhibition of cell motility by melatonin, impacts on cell invasion interactions were investigated; the images shown in Fig. 2B illustrate the suppression of cell invasion in the treated cells compared with the control.

Annexin-V FITC/PI staining and flow cytometry, which allows for the identification of early apoptotic cells, were utilized to evaluate apoptosis in human gastric cancer cells after exposure to 2 mM melatonin for 0 h to 48 h. As shown in Fig. 3A, the percentage of early apoptotic cells after treatment for 24 h was approximately 19.7-fold of that for the control cells (Fig. 3A), and the early apoptotic rate (Annexin-V FITC positive, PI negative) was significantly increased after 24 to 48 h (25% at 24 h and 35% at 48 h, Fig. 3B). These results indicated that melatonin had a pro-apoptotic effect on AGS cells.

Effects of melatonin on the phosphorylation of MAPK pathway components

Considering that treatment of AGS cells with melatonin inhibited cell viability and migration and induced apoptosis, the possible mechanisms were investigated by evaluating the effect on the elementary activation status of MAPKs. After treatment with 2 mM melatonin, p38, JNK and ERK phosphorylation was significantly induced in a time-dependent manner (Fig. 4A); the levels of p38, JNK and ERK served as internal controls, with the phosphorylated

Fig. 1. Effects of melatonin on the viability and colony formation of AGS cells. (A) AGS cells were treated for 0, 12, 24, 48 or 72 h with various concentrations of melatonin (0.25, 0.5, 1, 2 and 4 mM) or vehicle (0.2% DMSO). Viability was assessed by the CCK-8 assay. (B) Cells were incubated in the absence (cell control) or presence of 1 and 2 mM melatonin for 8 days; melatonin inhibits colony formation in AGS cells. The results are the means of three independent experiments. *P < 0.05; **P < 0.01 vs. control cells. MLT: melatonin.
protein level quantified considering 100% for the control (Fig. 4B). The results revealed clear increases in p-p38, p-JNK and p-ERK activity at 24 h and 48 h.

**Effect of melatonin on AGS cell pro-apoptosis and protease secretion via p38 and JNK signalling**

To determine whether the induction of Bax and caspase-3 and the inhibition of Bcl-2 secretion by melatonin occur mainly through p38-MAPK and JNK pathway activation, we investigated the effects of specific...
Li et al.: Melatonin Induces Apoptosis via JNK, P38 and NF-κB

Cellular Physiology and Biochemistry

© 2015 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cpb

Melatonin inhibits NF-κB activation via p38 and JNK pathways

To examine whether the inhibitory effect of melatonin on NF-κB expression is linked to the p38, JNK and ERK signalling pathways, the total protein level of NF-κB was analysed by Western blotting. First, to determine whether melatonin is involved in the inhibition of NF-κB, we examined the kinetic profile of p65 activation upon melatonin stimulation using phospho-p65 and total p65 antibodies. The results of Western blot analysis demonstrated that melatonin (2 mM) resulted in a marked decrease in phospho-p65 from 8 h to 48 h (Fig. 6A and B). In addition, alterations in the levels of p65 with respect to the melatonin dose were...
similar to changes in localization (Fig. 6C): melatonin-stimulated cells revealed extensive and clear cytoplasmic staining for p65, indicating inhibition of the nuclear translocation of activated phosphorylated-p65.

To further confirm that MAPK is an intermediate in the pathway that links responses to melatonin to NF-κB inhibition, endogenous p38, JNK and ERK expression was silenced in AGS cells by pretreatment with SB203580 (30 μM), PD98059 (30 μM), and SP600125 (30 μM) for 60 min and then incubated with or without melatonin (2 mM) for 24 h. Protein levels of Bax, Bcl-2, pro-caspase-3 and cleaved-caspase-3 were determined by Western blotting analysis. (B) The levels of Bax, Bcl-2, pro-caspase-3 and cleaved-caspase-3 proteins were quantified by densitometric analysis using the control as 100%, as shown just below the blot data. Data represent the mean ± S.E.M of at least three independent experiments. *P < 0.05, vs. control cells, **P < 0.05 vs. melatonin alone, C3: pro-caspase-3, CC3: cleaved-caspase-3, SB: SB203580, PD: PD98059, SP: SP600125, MLT: melatonin.

**Fig. 5.** Effects of melatonin, a p38 MAPK inhibitor (SB203580), an ERK inhibitor (PD98059), and a JNK inhibitor (SP600125) on the activities of Bax, Bcl-2, pro-caspase-3 and cleaved-caspase-3. (A) Cells were pre-treated with SB203580 (30 μM), PD98059 (30 μM) or SP600125 (30 μM) for 60 min and then incubated with or without melatonin (2 mM) for 24 h. Protein levels of Bax, Bcl-2, pro-caspase-3 and cleaved-caspase-3 were determined by Western blotting analysis. (B) The levels of Bax, Bcl-2, pro-caspase-3 and cleaved-caspase-3 proteins were quantified by densitometric analysis using the control as 100%, as shown just below the blot data. Data represent the mean ± S.E.M of at least three independent experiments. *P < 0.05, vs. control cells, **P < 0.05 vs. melatonin alone, C3: pro-caspase-3, CC3: cleaved-caspase-3, SB: SB203580, PD: PD98059, SP: SP600125, MLT: melatonin.

Melatonin enhances the effectiveness of cisplatin by suppressing AGS cancer cells

Melatonin affects AGS cell viability, as AGS cells exposed to increasing concentrations of melatonin exhibited reduced viability to different degrees. No significant toxicity was observed in human gastric mucosal GES-1 cells treated with melatonin at concentrations of 3 mM or less (Table 1). Therefore, 2 mM melatonin was selected as the physiological concentration for the experiments. In this study, an average AGS cell viability of 60% was detected by CCK-8 with 4 μg/ml cisplatin treatment. However, when cisplatin (4 μg/ml) was combined with
melatonin (2 mM), AGS cell viability was reduced to 47% (Fig. 7). This result indicated that cisplatin or melatonin reduces AGS cell viability and that the inhibitory effect is significantly increased by the combined treatment.

In a subsequent set of experiments, we examined whether the combination treatment-mediated anti-tumour effect was mediated by apoptosis. To this end, AGS cells were treated with 2 mM melatonin, 4 µg/ml cisplatin or both melatonin and cisplatin for 24 h, and apoptosis-related protein expression was detected by Western blotting using antibodies against Bax, Bcl-2, pro-caspase-3 and cleaved-caspase-3. Melatonin in combination with cisplatin resulted in significantly increased levels of Bax and cleaved-caspase-3 and

---

**Table 1.** Effect of melatonin and cisplatin on cell viability of AGS and GES-1 cells. *P < 0.05, vs. Cell control; bP < 0.05, vs. 4 µg/ml CDDP alone. CDDP:cisplatin; MLT:melatonin

<table>
<thead>
<tr>
<th>CDDP(µg/ml)</th>
<th>Viability(%)</th>
<th>CDDP(µg/ml)</th>
<th>Viability(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>67.8a</td>
<td>2</td>
<td>50.9a</td>
</tr>
<tr>
<td>4</td>
<td>59.9a</td>
<td>4</td>
<td>28.7a</td>
</tr>
<tr>
<td>6</td>
<td>44.2a</td>
<td>6</td>
<td>5.1a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MLT(mmol/L)</th>
<th>MLT(mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>87.3a</td>
</tr>
<tr>
<td>2</td>
<td>75.6a</td>
</tr>
<tr>
<td>3</td>
<td>39.8a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CDDP(µg/ml)+ MLT(mmol/L)</th>
<th>CDDP(µg/ml)+ MLT(mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4+2</td>
<td>47.0a</td>
</tr>
<tr>
<td>4+3</td>
<td>22.2a</td>
</tr>
</tbody>
</table>
decreased levels of Bcl-2 and pro-caspase-3 compared with untreated cells or those treated with melatonin or cisplatin alone (Fig. 8).

**Discussion**

Gastric cancer is one of the leading causes of cancer mortality worldwide, and the incidence can increase dramatically based on gender or ethnicity [29]. Drug therapy is a
promising strategy to halt the development of such tumours. Indeed, modern therapies provide effective ways to treat cancer but demonstrate certain toxicity and side effects, such as chemotherapy-induced peripheral neurotoxicity [30], endocrine therapy-induced menopause-like syndrome [31], or radiation-induced stomatitis [32]. However, melatonin could be effective in this field as a natural supplementary medicine. Although its therapeutic role has been studied by many investigators, the underlying mechanisms of its effects are poorly understood. Apoptosis, one of the potential mechanisms of anti-tumour activity, is a fundamental process in the development of various cell types. Thus, we investigated the induction of apoptosis by melatonin in gastric cancer cells.

In the current study, we demonstrated that melatonin inhibited AGS cell viability, migration and invasion in a dose- and time-dependent manner (Fig. 1, 2). Furthermore, melatonin was shown to induce apoptosis at suitable concentrations. Pro-apoptosis is considered to be the most appropriate method of cancer treatment, and Joo et al. reported that apoptosis is characterized by the activation of caspases related to cell viability [23]. Many previous studies have demonstrated that ERK pathway stimulation affects a survival signal that suppresses pro-apoptotic effects by activating p38 and JNK [33, 34]. Cisplatin induces apoptotic death and arrests cell growth through ERK activation [35], and paclitaxel, a potent inducer of G2/M cell cycle arrest and apoptosis, requires the activation of MAPK pathways (ERK and p38) [36].

Therefore, we determined whether melatonin induces apoptosis via MAPK (p38, JNK and ERK) signal transduction pathways in AGS cells. Our goal was to identify the underlying mechanism of the effect of melatonin as a potential apoptosis inducer. As shown by our Western blot analysis of MAPKs, p38, JNK and ERK phosphorylation was remarkably enhanced by melatonin at 24 h and 48 h (Fig. 4). Furthermore, induction of the mitochondria-mediated pathway of apoptosis by melatonin was indicated by increases in pro-apoptotic Bax and decreases in anti-apoptotic Bcl-2. These findings suggest that melatonin enhances the translocation of Bax protein to the mitochondria, permeabilization of the mitochondrial membrane and stimulation of caspase activity. Our results demonstrated that Bax and Bcl-2 expression was unchanged by PD98059 compared with melatonin alone, whereas the SP600125- and SB202190-treated cells exhibited increased Bax and decreased Bcl-2. These findings are in agreement with our previous hypothesis that melatonin induces apoptosis via the JNK and p38 signalling pathways, independently of ERK signalling. Moreover, the results showed that caspase-3 expression was responsive to SP600125 and SB202190 treatment, findings that are consistent with the results for Bax and Bcl-2 expression. Thus, a signalling molecule in apoptosis was activated by melatonin via p38 and JNK and promoted an increase in the Bax protein level, whereas the Bcl-2 cell survival protein level was decreased in the cytoplasm. Both Bax and Bcl-2 regulate caspase-3 activity. These findings are consistent with those of a previous report [23]. Recent studies have suggested a key role for p38 MAPK and JNK in mediating pathways leading to apoptosis and growth-inhibitory signals [37, 38]. Additionally, p38 MAPK and JNK trigger caspase-3 activation and are also necessary for the phosphorylation of apoptosis-related proteins, including Bax and Bcl-2, in cancer cells [23, 39]. Given these results, we speculate that melatonin promotes gastric cancer apoptosis by activating p38 and JNK, which trigger the overexpression of caspase-3. In contrast, PD98059 did not inhibit caspase-3 activity in AGS cells, revealing that melatonin-induced phospho-ERK may not be correlated with melatonin-mediated apoptosis.

The transcription factor NF-κB family comprises closely related protein dimers that bind to a common DNA sequence motif called the κB site [40]. Upon activation, NF-κB p65 is released from the IκB complex and translocates to the nucleus, where it induces the expression of genes encoding various proteins involved in suppressing apoptosis and inducing cellular proliferation, invasion and inflammation [41]. These target genes are important for the development of invasive tumours and include those encoding cell-cycle regulatory proteins, such as cyclin D1, and apoptosis-suppressor proteins, such as Bcl-2 and Bcl-XL [42]. Exceptional NF-κB activation is associated with the stimulation of proliferation and protection against apoptosis in malignant cells [43]. Many dietary phytochemicals have
been shown to suppress NF-κB, including curcumin [44], guggulsterone [45] and flavopiridol [46]. Here, we provide evidence that melatonin may inhibit the phosphorylation of NF-κB p65 (Fig. 6A and B). However, we cannot rule out the possibility that the observed effects of melatonin on the activation of signalling pathways could lead to NF-κB activation under short-term treatment and that the desensitization of those cascades could occur under long-term treatment (48 h), with those effects possibly contributing to the subsequent down-regulation of NF-κB-p65 phosphorylation. The latter raises the possibility that p38 MAPK and JNK activation by melatonin may be important for some of the pro-apoptotic activities of melatonin, including its inhibition of p65 phosphorylation. The present study provides evidence that p38 MAPK and JNK activation possibly inhibits the phosphorylation of p65 based on the observation that treatment with MAPK inhibitors (SB203580 and SP600125) prevented the ability of melatonin to suppress the phosphorylation of p65 (Fig. 6D). To determine whether the ERK pathway is also involved in the inhibition of p65 phosphorylation by melatonin, we examined the ERK kinase pathway, as well as p38 and JNK activity. In fact, under the same conditions, the ERK pathway did not inhibit the release of activated NF-κB, a result that contrasts with data showing that the phosphorylation of ERK1/2 regulates the phosphorylation (and activation) of NF-κB [47]. Indeed, an ERK inhibitor attenuated the force-mediated stimulation of NF-κB DNA binding in human periodontal ligament fibroblasts but not in the presence of a JNK or p38 MAPK inhibitor [48]. In addition, accumulating evidence indicates that the ERK1/2 inhibitor U0126 can suppress the IL-20-induced activation of IKK, the phosphorylation and degradation of IκBα, and the translocation of p65 subunits in bladder cancer cells [49]. It is interesting to note that the JNK/NF-κB cascade has been shown to participate in acetaldehyde-induced MMP-9 expression in hepatocellular cancer cells [50]. Moreover, Kim et al. found that reactive oxygen species activate CK2 via p38, which, in turn, induces NF-κB activation [51]. This information indicates that different MAPK family members are differentially involved in NF-κB activation under various stimulants and in different cell types [52].

There is evidence that both p38 MAPK and JNK activation promote cell apoptosis in tumour cells under some circumstances [53-55]. There is also extensive evidence showing that NF-κB activation suppresses apoptosis, most likely because NF-κB promotes the synthesis of proteins that can protect cells from apoptosis [56-59]. Our findings suggest that the tendency of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-κB activation by p38 and JNK. However, other factors are likely to be involved in these processes because incubating cells in the presence of the p38 kinase inhibitor SB203580 could not confer significant protection from melatonin-induced apoptosis [60, 61].

Based on our studies, we conclude that melatonin is a potent suppressor of cell viability and an inducer of apoptosis in gastric cancer cell lines. These results may be associated with promotion of the p38 MAPK and JNK machinery but not the ERK pathway. Indeed, p38 and JNK inhibitors prevented the ability of melatonin to suppress the phosphorylation of p65. These results suggest that p38 MAPK and JNK not only promote cell apoptosis via the mitochondria-mediated pathway of apoptosis (Bax and Bcl-2) but also inhibit protection against apoptosis (NF-κB). However, Bain et al. have recommend that using SP600125 as a JNK inhibitor should be discontinued in cell-based assays because of the lack of specificity of the compound [62]. Based on this shortcoming, our plan in further experiments is to inhibit protein expression via gene silencing, thereby enhancing the validity and reliability of our results.

Anticancer activity does not necessarily indicate changes in only cell proliferation or cell migration. Our data showed that melatonin could activate the ERK pathway in gastric cancer cells within the treatment times examined. A study that investigated the anticancer effect of paclitaxel demonstrated that ERK activation is associated with cell cycle arrest in G2/M phase [63]. Pro-death autophagy is the most recent anti-tumour activity to be described as a prosurvival mechanism, and studies have suggested that autophagy can promote cell death within different cellular contexts. Ordonez et al. reported that melatonin induced autophagy
in HepG2 cells, which was mediated by ER stress and JNK activation [64]. Bcl-2 and Bcl-xL, which are involved in cell apoptosis, also play crucial roles in autophagy [65], and inhibition of Bcl-2 and Bcl-xL expression and enhancement of JNK1/2 signalling may result in the activation of Beclin-1-mediated autophagy [66]. According to these findings and previous reports, we hypothesize that the anticancer effects of melatonin in gastric cancer cells may include cell cycle arrest and autophagy induction via the phosphorylation of MAPK.

Based on previous research, our next step is to study the effects of melatonin combined with chemotherapeutics in gastric cancer cells, possibly providing a reference for physicians to screen for effective chemotherapeutics. Cisplatin is a chemotherapy agent that inhibits cell proliferation and induces apoptosis in various tumour cells. However, the use of cisplatin alone in anti-cancer therapy may not be sufficiently powerful, and its anti-cancer effect may need to be reinforced by adjunct therapy. Melatonin is a widely used antioxidant drug, and its anti-tumour activities have been demonstrated in many studies [23, 67]. Due to its various functions and low cytotoxicity, melatonin may be used to improve cancer therapeutic efficiency in combination with other chemotherapeutic agents. As demonstrated in our study, we confirmed that melatonin can strengthen cisplatin-mediated antitumour effects in human gastric carcinoma cells by up-regulating the expression of Bax, down-regulating the expression of Bcl-2 and activating the caspase-dependent-apoptotic pathway. In summary, our findings suggest that melatonin may have potential as an anticancer reagent for gastric cancer therapy.

Acknowledgements

We thank Mrs. Yin Lihui (The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China) for providing technical support with cell culture and Miss. Song Xiaoxiao (Department of Otolaryngology, The First Affiliated Hospital of Wenzhou Medical University) for her help with the immunofluorescence assay. This work was supported by a grant from the Science and Technology Bureau of Wenzhou, Zhejiang Province, China (2014S0192).

Disclosure Statement

The authors declare no conflict of interest.

References


Zhou F, Yang Y, Xing D: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. *FEBs J* 2011;278:430-431.
